MaaT Pharma Advances Phase 2 Trial in ICI-Resistant NSCLC
Lyon, France, January 20, 2026 — MaaT Pharma, a late-stage clinical biotechnology company developing microbiome-driven immunotherapies, announced that the...
Alzheimer’s Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy GMP GMP compliance Immuno-Oncology immunology Immunotherapy Medical Devices MedTech medtech innovation Monoclonal Antibody NSCLC Oncology oncology innovation Orphan Drug orphan drug designation patient access Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory approval regulatory compliance targeted therapy
Lyon, France, January 20, 2026 — MaaT Pharma, a late-stage clinical biotechnology company developing microbiome-driven immunotherapies, announced that the...
